Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | TACR2 | P21452 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 7/20 | 0.40 |
| ▸ | CDC25B | P30305 | 6/20 | 0.40 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.38 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.38 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.38 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.38 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | GJB2 | P29033 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908255 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7545172 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7541321 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL6428120 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7616207 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7544031 | 1.00 | BCHE (0.44) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL9386370 | 0.96 | BCHE (0.45) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL8596282 | 0.96 | BCHE (0.45) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7440204 | 0.87 | NT5E (0.47) | BCHEACHEHTR1ANT5ETACR2 | |
| SCHEMBL7770786 | 0.84 | HTR1A (0.42) | BCHEACHEHTR1ANT5ETACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924396-B2 | α-haloenamine reagents | PHARMACIA CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1264836-B1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMA CO LTD (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-20040092770-A1 | Alpha-haloenamine reagents | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-6677487-B2 | COMBINING A TERTIARY AMIDE WITH A PENTAVALENT PHOSPHOROUS HALIDE IN A SOLVENT TO FORM AN ALPHA - HALOIMINIUM SALT AND CONVERTING THE ALPHA -HALOIMINIUM SALT TO THE ALPHA -HALOENAMINE WITH A BASE | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030080320-A1 | Alpha- haloenamine reagents | PHARMACIA CORPORATION | 2003-05-01 | — | — | US | disclosed |
| EP-1264836-A1 | Processes for the preparation of indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| EP-0688329-B1 | NOVEL PHOSPHOLIPID-SACCHARIDE CONJUGATES | GENZYME CORP (US) | 2002-05-15 | — | — | EP | disclosed |
| US-6171614-B1 | REDUCTIVE AMINATION; LIPOSOMES | EMORY UNIVERSITY | 2001-01-09 | — | — | US | disclosed |
| US-6071532-A | SYNTHETIC VACCINES; IMMUNOLOGY; MEDICAL DIAGNOSIS | EMORY UNIVERSITY (US) | 2000-06-06 | — | — | US | disclosed |
| US-5922860-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-07-13 | — | — | US | disclosed |
| US-5804564-A | Antitumor indolopyrrolocarbazole derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-09-08 | — | — | US | disclosed |
| EP-0760375-A1 | ANTITUMOR INDOLOPYPROLOCARBAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-5354853-A | Phospholipid-saccharide conjugates | GENZYME CORPORATION (US) | 1994-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030080320-A1 | Alpha- haloenamine reagents | HNMT, HDHD5, NISCH | BCHE 112/4885ACHE 119/4885HTR1A 1136/4885 |
| US-20040092770-A1 | Alpha-haloenamine reagents | HNMT, HDHD5, NISCH | BCHE 112/4885ACHE 119/4885HTR1A 1136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.